Cns Historical Income Statement
| CNSP Stock | USD 0.12 0.01 7.69% |
Historical analysis of Cns Pharmaceuticals income statement accounts such as Interest Expense of 14.2 K, Selling General Administrative of 3.6 M or Research Development of 14.8 M can show how well Cns Pharmaceuticals performed in making a profits. Evaluating Cns Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cns Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cns Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cns Pharmaceuticals is a good buy for the upcoming year.
Cns |
About Cns Income Statement Analysis
Cns Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cns Pharmaceuticals shareholders. The income statement also shows Cns investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cns Pharmaceuticals Income Statement Chart
Add Fundamental
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cns Pharmaceuticals. It is also known as Cns Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Cns Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.At this time, Cns Pharmaceuticals' Interest Expense is relatively stable compared to the past year. As of 11/26/2024, Research Development is likely to grow to about 14.8 M, though Operating Income is likely to grow to (17.9 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 14.0M | 15.3M | 18.9M | 9.9M | Research Development | 9.3M | 9.3M | 14.1M | 14.8M |
Cns Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Cns Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cns Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 44.2K | 3.3K | 9.3K | 7.0K | 13.8K | 14.2K | |
| Selling General Administrative | 2.0M | 4.4M | 4.7M | 6.0M | 4.8M | 3.6M | |
| Operating Income | (3.8M) | (9.5M) | (14.0M) | (15.3M) | (18.9M) | (17.9M) | |
| Net Income From Continuing Ops | (3.9M) | (9.5M) | (14.0M) | (15.3M) | (18.6M) | (17.7M) | |
| Ebit | (3.8M) | (9.5M) | (14.5M) | (15.3M) | (18.9M) | (17.9M) | |
| Research Development | 1.9M | 5.1M | 9.3M | 9.3M | 14.1M | 14.8M | |
| Total Operating Expenses | 3.8M | 9.5M | 14.0M | 15.3M | 18.9M | 9.9M | |
| Income Before Tax | (3.9M) | (9.5M) | (14.0M) | (15.3M) | (18.9M) | (17.9M) | |
| Total Other Income Expense Net | (44.2K) | (3.3K) | (9.3K) | (7.0K) | 13.9K | 14.6K | |
| Net Income Applicable To Common Shares | (7.4M) | (3.9M) | (9.5M) | (14.0M) | (12.6M) | (12.0M) | |
| Net Income | (3.9M) | (9.5M) | (14.5M) | (15.3M) | (18.9M) | (17.9M) | |
| Net Interest Income | (44.2K) | (3.3K) | (9.3K) | (7.0K) | 7.4K | 7.8K | |
| Depreciation And Amortization | 2.0K | 11.1K | 13.1K | 11.8K | 4.1K | 4.3K | |
| Other Operating Expenses | 3.8M | 9.5M | 14.0M | 15.3M | 18.9M | 11.4M | |
| Ebitda | (3.8M) | (9.4M) | (14.5M) | (15.3M) | (18.9M) | (17.9M) | |
| Income Tax Expense | 42.3K | 3.3K | 9.3K | 7.0K | (4.0) | (3.8) |
Pair Trading with Cns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Cns Stock
Moving against Cns Stock
| 0.72 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.7 | GILD | Gilead Sciences | PairCorr |
| 0.68 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.6 | KZR | Kezar Life Sciences | PairCorr |
| 0.59 | VRDN | Viridian Therapeutics | PairCorr |
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.